Biogen (BIIB) Misses Q4 EPS by 19c, Revenue Beats; Offers Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Biogen Reports Record Revenues for Both the Full Year and Fourth Quarter of 2017, $12.3 Billion and $3.3 Billion, Respectively
January 25, 2018 6:29 AM EST2017 total revenues grew 7% or 15% excluding hemophilia revenues*
2017 GAAP EPS decreased 30%, including a $1.2 billion charge due to U.S. tax reform
2017 non-GAAP EPS grew 8%
Company added seven clinical programs to neuroscience pipeline in 2017
Company provides 2018 full year revenue guidance of $12.7 to $13.0 billion
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Biogen Inc. (Nasdaq: BIIB) today reported full year and fourth quarter 2017 financial results, including:
Full year total revenues of $12.3 billion, a 7% increase versus the prior year or a 15% increase... More